We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.125 | -2.67% | 4.55 | 4.11 | 4.99 | 4.41 | 4.35 | 4.39 | 482,311 | 16:35:06 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.50 | 9.41M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 03/11/2020 11:07 | Courtesy of Davidbarnes. Numis came out with the following this morning. "with £87 million in gross proceeds the company is now fully funded to complete a single pivotal 900 patient 2 dose phase 3 trial across 20 countries, whilst also scaling up manufacturing to meet anticipated commercial demand.High quality trial design. In raising funds directly the company has greater control of the trial design. This is crucial given criticism of WHO solidarity study. (Paraphrase) SNG will have critical role to play as health systems deal with increased hospitalisations. Expect study to start immediately.Scientif | blakieboy7 | |
| 03/11/2020 10:26 | Could I have a coin for the guild too please Nobby? | sandcrab2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
